Edwards Beats on 11.2% Growth, Raises Full-Year Sales and EPS Guidance
EW sits 34% above its 52-week low of $74.66 on elevated volume (2.2× avg).
Summary
Q3 sales rose 10.5% to $1.72 billion, or 11.2% in constant currency, and adjusted EPS of $0.80 grew 19% year over year — management called the growth above expectations. TMTT did the heavy lifting at $207 million, up 44%, while TAVR grew 8.0% to $1.24 billion with stable global pricing and modest U.S. share gains. The company raised full-year 2026 sales growth guidance to about 11.5% from 10%-11%, lifted TAVR growth to 9.0%-9.5% from 8%-9%, and nudged TMTT to $780-$790 million from $760-$780 million; adjusted EPS guidance moves to $2.97-$3.05. GAAP results were hit by a $220.2 million impairment of an acquired IPR&D asset and fixed assets, which is why GAAP EPS was only $0.53, and net income came in at $307.5 million. This lands after a strong clinical stretch — the PROGRESS trial win and CLASP II TR data on Nov 2, plus the October PASCAL tricuspid approval — and offsets the October FDA high-risk recall warning on Commander M delivery systems. Q4 guidance of $1.67-$1.75 billion in sales and $0.61-$0.69 adjusted EPS implies the growth is expected to hold through year-end.
At the time of this announcement, EW was trading at $99.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $57.3B. The 52-week trading range was $74.66 to $100.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.